Stephen Mandel Zymeworks Inc. Transaction History

Lone Pine Capital LLC

  • $12.7 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$15.19 - $29.33 $14.8 Million - $28.6 Million
-976,735 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$39.12 - $54.99 $38.2 Million - $53.7 Million
976,735 New
976,735 $46.2 Million

Others Institutions Holding ZYME

# of Institutions
1
Shares Held
296K
Call Options Held
0
Put Options Held
0
View Full List

About Zymeworks Inc.

ZYME Quotes by TradingView
  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $525M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track Stephen Mandel's Portfolio

Track Stephen Mandel Portfolio

Follow Stephen Mandel (Lone Pine Capital LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lone Pine Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lone Pine Capital LLC and Stephen Mandel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email